Further detailed analysis of these 34 genes contributing to the anti-hypertension drugs, highlights the MAP Kinase specific nature of their action (Figure 5), underpinning their KRAS-directed mechanism of action. The gene discussed is KRAS; the disease is hypertensive disorder.